BIAFW

bioAffinity Technologies, Inc. Warrants represent the right to purchase shares of bioAffinity Technologies common stock at a predetermined exercise price during a specified time period. These warrants were issued as part of previous financing transactions and provide holders with leveraged exposure to bioAffinity's prospects in developing and commercializing cancer diagnostic technologies. The warrants trade separately from the common stock and appeal to investors seeking amplified participation in potential appreciation as the company advances its diagnostic platform, particularly CyPath Lung for early lung cancer detection. As derivative securities, these warrants' value derives from the underlying bioAffinity common stock price. When the stock price rises above the warrant's exercise price, the warrants gain intrinsic value. Additionally, warrants possess time value based on the remaining exercise period and stock volatility expectations. This leverage characteristic enables warrants to deliver larger percentage returns than the underlying stock during appreciation periods, though they also carry higher risk, potentially declining more sharply during downturns and expiring worthless if the stock price remains below the exercise price at expiration. bioAffinity Technologies is developing CyPath Lung, a non-invasive diagnostic test for early lung cancer detection using proprietary cellular staining technology and flow cytometry. The company's ability to successfully complete regulatory clearance, achieve commercialization, demonstrate clinical utility, secure reimbursement coverage, achieve adoption among physicians and patients, generate revenue growth, or reach other positive milestones could drive stock price appreciation, creating value for warrant holders. These instruments suit investors with higher risk tolerance who believe in bioAffinity's diagnostic technology and its potential to address the significant unmet need for better lung cancer early detection tools. The warrant investment thesis depends on successful regulatory approval, commercial launch execution, and market acceptance of CyPath Lung as a valuable diagnostic tool in the substantial lung cancer screening and diagnostic market.